PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma p...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chiara Tarantelli, Lisa Argnani, Pier Luigi Zinzani, Francesco Bertoni
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Acceso en línea:https://doaj.org/article/a69096643d264eb8a6a9cd140510591d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!